• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺激素受体抑制 miR-17 的表达以增强人肝癌细胞的肿瘤转移。

Thyroid hormone receptor represses miR-17 expression to enhance tumor metastasis in human hepatoma cells.

机构信息

Department of Biochemistry, College of Medicine, Chang-Gung University, Taoyuan, Taiwan, Republic of China.

出版信息

Oncogene. 2013 Sep 19;32(38):4509-18. doi: 10.1038/onc.2013.309. Epub 2013 Aug 5.

DOI:10.1038/onc.2013.309
PMID:23912452
Abstract

MicroRNAs (miRNAs) are thought to control tumor metastasis through direct interactions with target genes. Thyroid hormone (T3) and its receptor (TR) are involved in cell growth and cancer progression. However, the issue of whether miRNAs participate in T3/TR-mediated tumor migration is yet to be established. In the current study, we demonstrated that T3/TR negatively regulates mature miR-17 transcript expression, both in vitro and in vivo. Luciferase reporter and chromatin immunoprecipitation (ChIP) assays localized the regions responding to TR-mediated repression to positions -2234/-2000 of the miR-17 promoter sequence. Overexpression of miR-17 markedly inhibited cell migration and invasion in vitro and in vivo, mediated via suppression of matrix metalloproteinases (MMP)-3. Moreover, p-AKT expression was increased in miR-17-knockdown cells that led to enhanced cell invasion, which was blocked by LY294002. Notably, low miR-17 expression was evident in highly metastatic cells. The cell migration ability was increased by T3, but partially reduced upon miR-17 overexpression. Notably, TRα1 was frequently upregulated in hepatocellular carcinoma (HCC) samples and associated with low overall survival (P=0.023). miR-17 expression was significantly negatively associated with TRα1 (P=0.033) and MMP3 (P=0.043) in HCC specimens. Data from our study suggest that T3/TR, miR-17, p-AKT and MMP3 activities are interlinked in the regulation of cancer cell metastasis.

摘要

微小 RNA(miRNAs)被认为通过与靶基因的直接相互作用来控制肿瘤转移。甲状腺激素(T3)及其受体(TR)参与细胞生长和癌症进展。然而,miRNAs 是否参与 T3/TR 介导的肿瘤迁移的问题尚未确定。在本研究中,我们证明了 T3/TR 在体外和体内均负调控成熟 miR-17 转录本的表达。荧光素酶报告和染色质免疫沉淀(ChIP)实验将响应 TR 介导的抑制的区域定位到 miR-17 启动子序列的-2234/-2000 位置。miR-17 的过表达显著抑制了体外和体内的细胞迁移和侵袭,这是通过抑制基质金属蛋白酶(MMP)-3 介导的。此外,在 miR-17 敲低的细胞中,p-AKT 的表达增加,导致细胞侵袭增强,而 LY294002 可阻断这种增强。值得注意的是,高转移性细胞中 miR-17 的表达较低。T3 可增加细胞迁移能力,但 miR-17 的过表达可部分降低该能力。值得注意的是,TRα1 在肝细胞癌(HCC)样本中频繁上调,并与总体生存率降低相关(P=0.023)。miR-17 表达与 HCC 标本中的 TRα1(P=0.033)和 MMP3(P=0.043)呈显著负相关。我们的研究数据表明,T3/TR、miR-17、p-AKT 和 MMP3 活性在调节癌细胞转移中相互关联。

相似文献

1
Thyroid hormone receptor represses miR-17 expression to enhance tumor metastasis in human hepatoma cells.甲状腺激素受体抑制 miR-17 的表达以增强人肝癌细胞的肿瘤转移。
Oncogene. 2013 Sep 19;32(38):4509-18. doi: 10.1038/onc.2013.309. Epub 2013 Aug 5.
2
Thyroid hormone regulation of miR-21 enhances migration and invasion of hepatoma.甲状腺激素调节 miR-21 增强肝癌的迁移和侵袭。
Cancer Res. 2013 Apr 15;73(8):2505-17. doi: 10.1158/0008-5472.CAN-12-2218. Epub 2013 Feb 26.
3
Repression of microRNA-130b by thyroid hormone enhances cell motility.甲状腺激素抑制 microRNA-130b 增强细胞迁移能力。
J Hepatol. 2015 Jun;62(6):1328-40. doi: 10.1016/j.jhep.2014.12.035. Epub 2015 Jan 21.
4
Thyroid hormone receptor inhibits hepatoma cell migration through transcriptional activation of Dickkopf 4.甲状腺激素受体通过转录激活 Dickkopf 4 抑制肝癌细胞迁移。
Biochem Biophys Res Commun. 2013 Sep 13;439(1):60-5. doi: 10.1016/j.bbrc.2013.08.028. Epub 2013 Aug 16.
5
microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma.微小RNA-146a通过双重途径下调血管内皮生长因子来抑制肝细胞癌的癌转移。
Mol Cancer. 2015 Jan 21;14:5. doi: 10.1186/1476-4598-14-5.
6
Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma.甲状腺激素受体抑制肝癌中垂体肿瘤转化基因1的活性。
Cancer Res. 2008 Mar 15;68(6):1697-706. doi: 10.1158/0008-5472.CAN-07-5492.
7
Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer.甲状腺激素通过Met/FAK途径对肝癌中脂质运载蛋白2的介导调控
Oncotarget. 2015 Jun 20;6(17):15050-64. doi: 10.18632/oncotarget.3670.
8
Sulfatide epigenetically regulates miR-223 and promotes the migration of human hepatocellular carcinoma cells.硫酸脑苷脂通过表观遗传调控 miR-223 并促进人肝癌细胞的迁移。
J Hepatol. 2014 Apr;60(4):792-801. doi: 10.1016/j.jhep.2013.12.004. Epub 2013 Dec 11.
9
Derepression of c-Fos caused by microRNA-139 down-regulation contributes to the metastasis of human hepatocellular carcinoma.微小 RNA-139 的下调导致 c-Fos 的去抑制,从而促进了人肝癌的转移。
Cell Biochem Funct. 2013 Jun;31(4):319-24. doi: 10.1002/cbf.2902. Epub 2012 Sep 23.
10
Cathepsin H regulated by the thyroid hormone receptors associate with tumor invasion in human hepatoma cells.甲状腺激素受体调控的组织蛋白酶 H 与肝癌细胞的侵袭转移有关。
Oncogene. 2011 Apr 28;30(17):2057-69. doi: 10.1038/onc.2010.585. Epub 2011 Jan 10.

引用本文的文献

1
Mechanistic study of quercetin in the treatment of thyroid cancer with diabetes based on network pharmacology and experiments.基于网络药理学和实验的槲皮素治疗糖尿病合并甲状腺癌的机制研究
Front Endocrinol (Lausanne). 2025 Jun 12;16:1537799. doi: 10.3389/fendo.2025.1537799. eCollection 2025.
2
'Investigation of miRNAs That Affect the PI3K/AKT/mTOR Signaling Pathway in Endometrial Cancer'.影响子宫内膜癌中PI3K/AKT/mTOR信号通路的微小RNA的研究
Cell Biochem Biophys. 2025 Feb 21. doi: 10.1007/s12013-025-01694-6.
3
Understanding Gene Involvement in Hepatocellular Carcinoma: Implications for Gene Therapy and Personalized Medicine.
了解基因在肝细胞癌中的作用:对基因治疗和个性化医疗的启示
Pharmgenomics Pers Med. 2024 May 7;17:193-213. doi: 10.2147/PGPM.S431346. eCollection 2024.
4
Biological implications and clinical potential of invasion and migration related miRNAs in glioma.胶质瘤中侵袭和迁移相关微小RNA的生物学意义及临床潜力
Front Integr Neurosci. 2022 Nov 21;16:989029. doi: 10.3389/fnint.2022.989029. eCollection 2022.
5
The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum.实体非甲状腺癌患者甲状腺功能减退的临床相关性:一个诱人的难题。
J Clin Med. 2022 Jun 14;11(12):3417. doi: 10.3390/jcm11123417.
6
Targeting Thyroid Hormone/Thyroid Hormone Receptor Axis: An Attractive Therapy Strategy in Liver Diseases.靶向甲状腺激素/甲状腺激素受体轴:肝脏疾病中一种有吸引力的治疗策略。
Front Pharmacol. 2022 Jun 2;13:871100. doi: 10.3389/fphar.2022.871100. eCollection 2022.
7
CircSEC24A (hsa_circ_0003528) interference suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells via miR-421/MMP3 axis.环状 RNA SEC24A(hsa_circ_0003528)通过 miR-421/MMP3 轴抑制肝癌细胞上皮-间充质转化。
Bioengineered. 2022 Apr;13(4):9049-9062. doi: 10.1080/21655979.2022.2057761.
8
Mislocalization of Cancer-associated Thyroid Hormone Receptor Mutants.癌症相关甲状腺激素受体突变体的错误定位
Nucl Receptor Res. 2020;2020.
9
The Intriguing Thyroid Hormones-Lung Cancer Association as Exemplification of the Thyroid Hormones-Cancer Association: Three Decades of Evolving Research.甲状腺激素-肺癌关联:甲状腺激素-癌症关联的范例研究进展 30 年。
Int J Mol Sci. 2021 Dec 31;23(1):436. doi: 10.3390/ijms23010436.
10
Low thyroid hormone receptor alpha-2 (THRα-2) tumor expression is associated with unfavorable tumor characteristics and high breast cancer mortality.甲状腺激素受体α-2(THRα-2)肿瘤表达水平低与肿瘤不良特征和高乳腺癌死亡率相关。
Breast Cancer Res. 2021 Dec 20;23(1):117. doi: 10.1186/s13058-021-01496-7.